News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Pulsenmore partners with Ouma Health to expand remote prenatal care
Pulsenmore and Ouma Health announced a partnership to increase access to remote prenatal care services across the United States. Details on scope, rollout timeline, and clinical outcomes remain unclear.
Quantum Computing Inc. Acquires NHanced Semiconductors
Quantum Computing Inc. has completed its acquisition of NHanced Semiconductors, Inc. Details on deal terms and strategic rationale remain under wraps.
Agomab Starts Phase 2b Trial for Fibrostenosing Crohn's in 2026
Agomab's ontunisertib cleared FDA alignment and regulatory approvals for a 320-patient study targeting a stricture disease affecting 46% of Crohn's patients. Here's what the trial design tells you about the unmet need.
Lundbeck to Present Bocunebart Phase 2b Migraine Data at EAN 2026
Lundbeck will present five migraine studies at the European Academy of Neurology Congress in June 2026, including primary phase 2b data for bocunebart, an investigational PACAP pathway inhibitor for patients who failed prior preventive treatments.
Nephrology trials cost $30M for Phase III. Biomarkers cut time to decision.
Kidney disease trials run 34.7 months on average. A nephrologist explains why biomarkers like NGAL and KIM-1 let sponsors predict failure early—and what regulators still won't accept.
NVIDIA BioNeMo Toolkit Gives AI Agents Life Science Tools and Rules
NVIDIA unveiled BioNeMo, a toolkit designed to let AI agents run R&D workflows autonomously. Nearly 50 partners are already adopting it; here's what's in the box.
Haisco Nets $40M Upfront From Nuvectis for Two Drug Candidates
Haisco signed an exclusive licensing deal giving Nuvectis worldwide rights to develop oncology and complement therapies. The Chinese biotech receives $40M now and up to $1.4B in milestone payments.
Boehringer partners with Combotope on glycan-targeting cancer antibodies
Boehringer Ingelheim and Combotope Therapeutics signed a research deal to advance tumour-selective antibodies using Combotope's SMART-Phage platform. The collaboration targets multiple oncology programs with potential milestone and royalty payments.
Lilly and Oura Bundle GLP-1 Drugs With Wearable Ring for Obesity Care
Eli Lilly's telehealth platform now offers free Oura Ring sizing kits to patients taking weight-loss medications. The move signals pharma's shift from drug-only to integrated behaviour and biometric tracking.
Brensocatib Approved: Bronchiectasis Gets Its First Targeted Drug
Insmed's Brinsupri became the first FDA-approved treatment targeting the disease mechanism itself, not just symptoms. Here's what the pipeline looks like next.
VectorBuilder and MaxCyte Partner on Safer Cell Therapy Manufacturing
Two biotech firms are combining plasmid and electroporation tech to reduce production costs and safety risks in CAR-T and CAR-NK manufacturing. Here's what changes for drug developers.
Nvidia BioNeMo Agents Speed Protein Design 2x, Now Live with Lilly and Natera
Nvidia's BioNeMo Agent Toolkit automates scientific workflows across protein design, drug discovery, and genomic analysis. Early users include Eli Lilly and Natera. Here's what the toolkit does and who should test it.